influenced in different age groups when deaths within 90 days were taken into account. Background. Patients who die within 90 days of commencing renal replacement therapy (RRT ) may be Conclusions. The incidence of deaths within 90 days from the start of RRT was 3.9%, with a marked recorded by some centres and not others, and hence data on mortality and survival may not be comparable. variation between countries ranging from 1.8% to 11.4%, which probably reflects mainly differences in However, it is essential to compare like with like when analysing differences between modalities, centres and reporting these deaths, although variable selection criteria for RRT may contribute. Deaths within 90 days registries. It was decided, therefore, to look at the incidence of deaths within 90 days in the ERA-EDTA were significantly more frequent in elderly patients with more early deaths resulting from cardiac and Registry, and to try to define the characteristics of this group of patients. social causes, while vascular causes of death and malignancy were more common in those dying after 90 days. Methods. Between 1 January 1990 and 31 December 1992, 78 534 new patients started RRT in 28 countries Patient survival analyses should take into account deaths within 90 days from the start of RRT, particuaffiliated to the ERA-EDTA Registry. Their mean age was 54 years and 31% were over 65 years old. Eighty-larly when comparing results between modalities, countries and registries. two per cent of the patients received haemodialysis (HD), 16% peritoneal dialysis (PD) and 2% had preKey words: comorbidity; early deaths; elderly patients; emptive transplantation as first mode of treatment. mortality; renal replacement therapy; survival Results. From January 1990 to March 1993 the overall incidence of deaths was 19% and 4% of all patients died within 90 days from the start of RRT. Among those dying within 90 days 59% were over 65 years Introduction compared to 53% over 65 years in those dying beyond this time (P<0.0001). The modality of RRT did not In recent years there has been a rapid rise in acceptance influence the distribution of deaths before and after 90 rate for renal replacement therapy (RRT ) worldwide, days. Vascular causes and malignancy were more resulting in a considerable expansion of the pool of common in those dying after 90 days, while there were patients receiving treatment for end-stage renal disease more cardiac and social causes among the early deaths. ( ESRD). Registry data analysis for 1995 showed that Mortality from social causes was twice as common in the annual rate of expansion in this pool in the the elderly, who had a significantly higher chance of European Community, the USA and Japan was 8.2%, dying from social causes within 90 days compared to 7% and 7.8% respectively, with a total number of those aged under 65 years. The overall incidence of patients alive on RRT at the end of 1995 exceeding deaths within 90 days was 3.9% but there was a wide 700 000 in these three registries [1, 2] . variation between countries, from 1.8% to 11.4%.
improved as much as expected. Life expectancy for
The tabular analyses compared patients dying within 90 ESRD patients aged 49 years is similar to that of days (day 90 was included in this group) to patients dying patients with certain malignancies such as carcinoma after day 90 from the start of RRT. Patients lost to followof colon [3] . Also the increased acceptance of older up were included in the tabular analyses, and these comparand more ill patients has increased early mortality. In isons provided results regarding age distribution at start of the 1991 USRDS report, the mortality within 90 days RRT, sex, first MOT and cause of death. Social causes of from starting RRT during 1989 increased from 11% death included refusal of treatment, suicide and withdrawal of treatment. Under miscellaneous causes of death are listed in the 65-69 age group, to 26% in the 85+ age group 11 causes including malignancy, cachexia, dementia, [4] . In the latter group, the 90-day mortality rose from obstructive airways disease and sclerosing peritonitis.
21% to 26% between 1983 and 1989, suggesting that Comparisons between groups were carried out using the comorbidity over this 7 year period was increasing
Pearson chi-square with Fisher's exact test where within the 85+ age group accepted for RRT.
appropriate.
In a recent multicentre European study involving Patient survival analyses were carried out within the SPSS seven centres in five countries, a variation in 90-day using Life Tables, including and excluding deaths within 90 mortality from the start of RRT was associated with days from start of RRT. Survival of subgroups was compared age and comorbidity [5] . In this study overall survival using the Wilcoxon (Gehan) test. Patients lost to follow-up was significantly affected by early mortality, suggesting were excluded. Survival of all patients on RRT was estimated from first MOT to death or to the end of follow-up, and all that deaths within 90 days should be taken into account data on survival were calculated without considering the when comparing results between centres.
number of types of RRT used in a given patient. Therefore, Consideration of early deaths is also relevant when patients who started dialysis and subsequently received renal comparing survival figures between registries. USRDS transplants were included in the survival analyses.
reports, for example, consider the survival of patients under 65 years only beyond 90 days for all treatment modalities because of incomplete data documenting Results early deaths [4] . By contrast, patient survival analyses from the ERA-EDTA Registry include deaths within
Overall incident mortality 90 days, although these events have most likely been under-reported to a variable degree by contributing The total number of deaths from January 1990 to centres.
March 1993 was 14 808 (18.9% mortality of the incident It is essential to compare like with like, and for this population) ( Table 1) . Of these deaths 3047 occurred reason it was decided to define the incidence of and within 90 days of starting RRT, which represents 3.9% factors related to deaths within 90 days of starting of the incident population and 20.6% of the total RRT in the ERA-EDTA Registry in order to assess deaths. The remaining 11 761 deaths occurred after 90 their importance and enable comparisons to be made days giving a 15% incident mortality and accounting more accurately with other registries.
for 76.4% of the total deaths. In Table 1 columns '% of patients' and '% of deaths' were both calculated with the number of dead patients and they are referred
Subjects and methods
to per cent of dead of the incident population and per cent of total deaths respectively within each of the Between 1 January 1990 and 31 December 1992, 78 534 new three categories of deaths within 90 days, over 90 days patients started RRT in 28 countries affiliated to the and total deaths.
ERA-EDTA Registry. The number of contributing centres
The incident mortality within 90 days in males and was 2248, 2344 and 2561 during the years 1990, 1991 and females was identical at 3.9%. The proportion of males 1992 respectively. The methods of data collection used by in those dying within 90 and after 90 days was 59% the ERA-EDTA Registry have previously been described and 58% respectively. [6 ] . Patients with incomplete or erroneous information and seven countries with inconsistent data have been excluded.
The number of new patients entering RRT was 26 647, Mortality within 90 days in the elderly 26 611 and 25 276 in 1990, 1991 and 1992 respectively. The average response rate to the EDTA patient questionnaire There was a difference in the mean age (SD) between during this period, excluding the above mentioned seven the two groups of early and later deaths, which was countries, was 83%, 82% and 73% respectively. After 1992 significantly higher in those dying within 90 days at the response rate declined and this was the main reason for 65.0 (14.0) years compared to 63.1 (14.3) years for studying the years 1990-92. those dying after 90 days, P<0.001. The 90-day incidMales accounted for 46 254 patients (59%) and females ent mortality ranged from 0.8% in the <15 age group 32 280 (41%). The mean age was 54 years and 31% of to 9.8% in the 75+ age group, while the respective patients, defined as elderly, were over 65 years old. Of the mortality from day 90 onwards ranged from 4.8% to total, 82% of patients received HD (hospital and home HD), 31.2% ( Table 1 ). The 55-64 year age group had a 16% received PD (intermittent, CAPD and CCPD) and 2% mortality of 3.7% and 15.8% within 90 days and after had pre-emptive transplantation as first mode of treatment (MOT ). mortality for all ages in the two groups, 3.9% and 15% respectively. However, in the oldest age groups, 65-74 years and 75+ years, the mortality was significantly higher in those who died within 90 days from the start of RRT. There were more patients aged over 65 years dying within 90 days (59%), compared to those dying after 90 days (53%, P<0.0001) ( Figure 1 ).
Primary renal disease and mortality within 90 days
The overall 90-day incident mortality in patients with standard PRD, which includes glomerulonephritis (GN ), chronic pyelonephritis, drug nephropathies, polycystic kidneys and hereditary nephropathies was 2.1%. It ranged from 0.9% in hereditary nephropathies ( Table 1) . This was also the case for percentages of patients are shown in Table 1 . There were significantly those who died after day 90. In both groups mortality more patients over 65 years dying within 90 days compared to those dying beyond day 91, 59% vs 53%, P<0.0001.
due to hereditary nephropathies and polycystic kidneys D. Tsakiris et al. 2346 was the lowest compared with other PRD groups. Also fewer deaths occurred in patients with standard PRD within 90 days compared to beyond 90 days, overall 26.2% against 31.9% ( Figure 2 ). There were also fewer deaths in diabetic patients within 90 days at 18.9% compared to 25.4%. In contrast there were more early deaths in patients with unknown PRD, renovascular disease (RVD), multisystem and miscellaneous diseases, 18% compared to 14.3%, 17.2% compared to 15.8%, 10.4% compared to 7.8% and 9.3% compared to 5.4% respectively. Table 1 , and Table 2. ( Table 1 ). In the small number of patients who had Cardiac and social causes of death were more frequent in patients pre-emptive transplantation as first MOT the incident dying within 90 days, while vascular and miscellaneous causes, including malignancy, were more common in those dying beyond mortality was much lower at 1.3% and 1.8% within day 90.
First MOT and mortality in 90 days
and beyond 90 days respectively although the percentage of total deaths accounted for by pre-emptive transplantation was three times higher within (0.7%) than beyond (0.2%) 90 days ( Table 1) .
Causes of death
Cardiovascular causes were responsible for more than half of the deaths. The causes of death within and beyond 90 days are shown in Table 1 and Figure 3 and the subdivision of causes under the heading of cardiac and vascular are shown in Table 2 . Vascular causes of death, 60% of which were due to cerebrovascular accident, and malignancy were more common in those patients dying after 90 days compared to those dying within 90 days, 15% vs 12.4% (P<0.00025) and 6.5% vs 5%, (P<0.0016 respectively). By contrast, more (P<0.01) respectively. Although the difference seems small, social causes of death were more common within than beyond 90 days (5% vs 4.2%: P<0.01) as shown in Table 2 .
Mortality from social causes was more than doubled in the elderly. Of the deaths due to social causes 5.7% occurred in patients over 65 years and the remaining 2.7% in the younger patients. Within this group withdrawal of treatment accounted for 3.2% and 1.2% of deaths in the older and younger patients respectively. Furthermore patients over 65 years had a higher chance of dying from social causes within the first 90 days than beyond this time, 82% against 69% (P<0.01) ( Figure 4) . Table 3 shows the incidence of deaths within 90 days in the countries included in this study. The average Fig. 2 . Distribution of deaths within 90 days and beyond day 90 by primary renal disease in new patients starting RRT in 1990-92. incidence was 3.9% and there was a wide variation Numbers and percentages of patients are shown in Table 1 . Standard from high figures in Norway and Sweden at 11.4%, PRDs and diabetes were less frequent, while unknown PRDs, RVDs, down to countries including Greece, Ireland, Spain multisystem and miscellaneous diseases were more common in and Switzerland with an incidence of around 2%. Lack patients dying within 90 days compared to those dying beyond day 90.
Variation between countries in the 90-day mortality
of uniformity in reporting deaths to the Registry is thought to be the major reason for these differences although different selection criteria in the acceptance Table 3 . Incidence of patients dying within 90 days from start of of patients for RRT may have contributed. one of the strongest predictors of mortality [3, 4] , an indirect measure of the greater comorbidity comes reporting an overall 90-day mortality of 8.7%, and emphasizing the need for uniform methodology in the from the increased proportion of patients with RVD and multisystem diseases (including diabetes) accepted collection and analysis of data to enable valid comparisons to be made between centres and registries [5] . for RRT, which rose from 7.6% and 10.8% in 1979 [8] to 12.3% and 19.1% respectively in this [1990] [1991] [1992] There has also been a problem in comparing registry data not only because of variations in the quality of cohort.
RRT in different countries

Patient survival
In 1989 the 90-day incident mortality in the USA the data but also because of differences in the methods applied to mortality and survival analyses. For for elderly RRT patients was much higher than in Europe, ranging from 11% in the 65-69 year age group example, USRDS reports exclude deaths from 0 to 90 days in patient survival probabilities [4] , in the to 26% in the 85+ age group [4]. For younger patients there have been no statistics from USRDS, nor has Canadian haemodialysis morbidity study, the eligibility criterion was survival on HD for 1 month from initiany other national registry reported results on this topic. ation of therapy [11] and ERA-EDTA Registry reports have included 90-day mortality in their survival The only reports on early deaths come from single centre and small multicentre studies on both sides of analyses.
Although both in the general population and among the Atlantic. Wright, in a single centre study of 138 patients, reported that 32% of all deaths occurred dialysis patients females had a lower overall mortality rate in Europe [12,13] and in the USA [4] compared within 90 days from the start of RRT [9] . Using a simple classification scheme based on age and comor-to males, this study shows that the 90-day mortality was identical between males and females. This suggests bidity, he successfully predicted the risk of early deaths and identified a group of patients predicted to do well. that factors which contribute to better survival for females in the long-term do not apply to early deaths. Khan et al., adopting the same risk stratification criteria in two units in Scotland, reported an identical As expected, there was a strong association between 90-day mortality and old age. In the age groups up to figure of 32% in a population of 375 patients. The overall survival of this group was 65% at 2 years but 45-54 years, early mortality was much lower when compared to the overall average of 3.9%. For the age this masked a wide spread of survivals, ranging from 35% in the high risk group to 86% in the low risk group of 55-64 years early mortality was close to the average, but for the oldest age groups of 65-74 and group [10] . Khan et al. extended these findings in a multicentre study involving seven European centres, 75+ years it increased significantly to 6.3% and 9.8%
Deaths from renal replacement therapy 2349 respectively ( Table 1 ). In the USA the 90-day mortality to 9.6 in the 65-74 age group and to 19.4 in the 75+ group [4]. In our study deaths from withdrawal of for 1989 was nearly double that in Europe, 12.5% for the 65-74 age group and 21% for the 75+ age group treatment represented 2.3% of the total deaths (341 from 14 808) and were more common in patients >65 [4] . Also in the USA early mortality in the oldest age group (85+ years) increased from 21% to 26% between years (3.2%) compared to those <65 age group (1.2%) but these figures are much lower than in the USA. The 1983 and 1989, suggesting that comorbidity within this age group in patients accepted for RRT was becoming high rates of dialysis withdrawal in the USA may be due in part to acceptance of more very old patients more pronounced over these 7 years.
The cause of ESRD is one of the strongest predictors with multiple comorbid factors. Also, in the USA patients developing ESRD after the age of 65 are of mortality. Diabetic patients on RRT have approximately twice the mortality risk compared to patients immediately eligible for Medicare coverage and the USRDS data are therefore likely to be more complete with glomerulonephritis [3] . In the 1985 incident cohort of USRDS, the age, race and sex adjusted in comparison with the voluntary ERA-EDTA Registry. patient survival (after 90 days) at 5 years was 49% in patients with primary renal diseases e.g. glomerulo-
In this analysis the 90-day mortality ranged from 1.8% in Ireland to 11.4% in Norway and Sweden. In nephritis, 41% in patients with hypertension and 24% in diabetic patients [4] . Similar results were reported a previous Registry report which compared patient survival (including deaths within 90 days) of elderly from the ERA-EDTA Registry (including deaths within 90 days) in patients starting treatment since patients in selected countries, it was noted that in Nordic countries half of the patients had died by the 1980, with the best 5 year survival in patients with polycystic disease and progressively lower survival in end of the first year as opposed to other European countries in which patient survival was around 70% to those with glomerulonephritis, pyelonephritis, RVD and diabetes [12] . In this study the 90-day incident 80% [15] . Acceptance rates did not appear to differ between Nordic and other selected countries, although mortality was 2.1% in patients with standard primary renal diseases and three times higher at 6.4% in patients there was a higher prevalence of diabetic nephropathy and more transplanted patients in the older age groups with RVD, diabetes, multisystem and miscellaneous diseases ( Table 1) . Patients with polycystic kidneys in the Nordic countries. In this study, acceptance of diabetic patients for RRT varied widely from 1% in and hereditary nephropathies were the least likely to die within 90 days among those with all causes of Romania to 25% in Finland. However, this could only partly explain differences in 90-day mortality, which ESRF, while diabetic patients were at a higher risk of dying within 90 days compared to patients with stand-was higher in diabetic patients compared to those with standard PRD, as significantly more diabetic patients ard PRD ( Table 1) , although the proportion of deaths in diabetic patients dying beyond day 90 was higher died beyond day 90. Nevertheless, these points suggest that different selection criteria for RRT, as well as than for those dying within 90 days (Figure 2) .
With regard to first MOT, there was no major variations in comorbidity, do exist across countries in Europe. In a recent review on evolution of RRT in difference in the 90-day incident mortality between patients receiving HD or PD (4% vs 3.7%) as first central and eastern Europe, Rutkowski et al. reported that availability of these facilities varied widely between treatment. By contrast, Innes et al. reported significantly greater use of HD compared to CAPD in patients these countries and described a dramatic change in recent acceptance of ESRD patients [16 ] . In this cohort dying early [14] . They related these deaths to late referral with the need for emergency haemodialysis among the five countries of central and eastern Europe, Romania, which appeared to have the strictest selection and stressed the importance of nephrological assessment before the patient reached ESRD. The proportion criteria for RRT, had the lowest 90-day mortality rate at 2.9%, while Hungary, with the larger fraction of of deaths within 90 days in patients undergoing preemptive transplantation as first MOT was three times elderly patients, had the highest at 5.8% amongst these countries ( Table 3 ). Yet none of these countries were higher in this study compared to deaths beyond day 90, due presumably to causes related to the operation among those with the lowest 90-day mortality in Europe, such as Ireland, Greece, Spain and and early post-operative period.
More than half of the total deaths in the 1990-1992 Switzerland. Most likely this is because, apart from patient related factors such as comorbidity which may incident cohort were due to cardiovascular causes, followed by miscellaneous causes and infections. influence outcome, treatment related factors and possibly a centre effect are also important for patient Cardiac and social causes of death were more common in those dying within 90 days, while vascular causes survival. Such a centre effect was described in the Biomed multicentre study by Khan et al. [5] . In that and deaths from malignancy were more common beyond day 90 ( Tables 1, 2, Figure 3 ). In the 1991 study the 90-day mortality rate ranged from 2.7% to 13.1% across seven centres in five European countries, USRDS report cardiac causes of death also predominated between days 0 and 90 in patients over 65 years, which is similar to the range observed in this study.
Stratification of patients to a low, medium and high but withdrawal of treatment was the next most common, both in the first 90 days and overall.
risk group based on age and comorbidity revealed a variable fraction of high risk patients among centres Furthermore, these deaths in the USA increased from 1.6 per 1 000 patient years in the 45-64 age group ranging from 13.7% to 34.1%. Comparison of patient
